Therapeutic Asset Ratings

622 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Doxycyclin Breast Cancer	Swiss Cancer Institute	P2	CC (46)
ds-6051b Breast Cancer	Megan Kruse, MD	P2	CC (46)
Dupilumab Breast Cancer	Ottawa Hospital Research Institute	P2	CC (46)
FAPI74 Breast Cancer	Randy Yeh	P2	CC (46)
Fianlimab Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (46)
Flibanserin Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CC (46)
Gsk 5733584 Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (46)
Hcq Breast Cancer	Abramson Cancer Center at Penn Medicine	P2	CC (46)
her3-dxd Breast Cancer	Daiichi Sankyo	P2	CC (46)
Herombopag Olamine Tablets Breast Cancer	Fujian Cancer Hospital	P2	CC (46)
Hrs-4508 Breast Cancer	Fudan University	P2	CC (46)
ibi354 Breast Cancer	Fudan University	P2	CC (46)
IMMUNOGLOBULIN G, ANTI-(HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER Breast Cancer	M.D. Anderson Cancer Center	P2	CC (46)
Iparomlimab Breast Cancer	Tianjin Medical University Cancer Institute and Hospital	P2	CC (46)
Irx 2 Breast Cancer	Providence Health & Services	P2	CC (46)
js207 Breast Cancer	Fudan University	P2	CC (46)
Lucanisatuzumab Breast Cancer	Sun Yat-sen University	P2	CC (46)
Lunresertib Breast Cancer	Canadian Cancer Trials Group	P2	CC (46)
Menthol Breast Cancer	Necmettin Erbakan University	P2	CC (46)
Nbp Breast Cancer	Conjupro Biotherapeutics, Inc.	P2	CC (46)
nbq72s Breast Cancer	Nantong Bencao Quadriga Medical Technology Co. Ltd.	P2	CC (46)
N-DESMETHYL-4-HYDROXYTAMOXIFEN Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (46)
Netupitant Breast Cancer	Chinese University of Hong Kong	P2	CC (46)
Ocifisertib Breast Cancer	Canadian Cancer Trials Group	P2	CC (46)
Onlife® Breast Cancer	Centre Georges Francois Leclerc	P2	CC (46)

Showing 301 to 325 of 622 assets

PreviousPage 13 of 25Next